Language: BG BG
nav.cta
← Back to results
Active (not recruiting) Phase 2 2025-521710-25-00

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)

Phase 2 – studying effectiveness and dosage
Conditions: Lewy Body Dementia Psychosis (LBDP)

Sponsor: Acadia Pharmaceuticals Inc.

trial.available_in: БГ
Overview
Trial status: Authorised Change from Baseline in SAPS-LBDP total score at Week 6
Who can participate
Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 77 participants
Interventions
Placebo for ACP-204 capsules
Drug
Locations 4
Bulgaria (1)
Czech Republic (1)
France (1)
Italy (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
29.10.2025
Registry ID
2025-521710-25-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.